BR112016015285A2 - pirimidina imidazol aminas como moduladores da atividade de quinase, seus usos e seu processo de preparação, composição farmacêutica, e kit - Google Patents
pirimidina imidazol aminas como moduladores da atividade de quinase, seus usos e seu processo de preparação, composição farmacêutica, e kitInfo
- Publication number
- BR112016015285A2 BR112016015285A2 BR112016015285A BR112016015285A BR112016015285A2 BR 112016015285 A2 BR112016015285 A2 BR 112016015285A2 BR 112016015285 A BR112016015285 A BR 112016015285A BR 112016015285 A BR112016015285 A BR 112016015285A BR 112016015285 A2 BR112016015285 A2 BR 112016015285A2
- Authority
- BR
- Brazil
- Prior art keywords
- modulators
- kit
- pharmaceutical composition
- preparation process
- kinase activity
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- -1 pyrimidine imidazole amines Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461938343P | 2014-02-11 | 2014-02-11 | |
| PCT/US2015/015136 WO2015123174A1 (en) | 2014-02-11 | 2015-02-10 | Pyrimidine imidazole amines as modulators of kinase activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016015285A2 true BR112016015285A2 (pt) | 2017-08-08 |
| BR112016015285A8 BR112016015285A8 (pt) | 2020-06-09 |
Family
ID=52589790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016015285A BR112016015285A8 (pt) | 2014-02-11 | 2015-02-10 | pirimidina imidazol aminas como moduladores da atividade de quinase, seus usos e seu processo de preparação, composição farmacêutica, e kit |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9434714B2 (pt) |
| EP (1) | EP3105224A1 (pt) |
| JP (1) | JP6560243B2 (pt) |
| KR (1) | KR20160110953A (pt) |
| CN (1) | CN105980375A (pt) |
| AU (1) | AU2015217397B2 (pt) |
| BR (1) | BR112016015285A8 (pt) |
| CA (1) | CA2935600A1 (pt) |
| IL (1) | IL246973A0 (pt) |
| MX (1) | MX2016010268A (pt) |
| RU (1) | RU2690679C2 (pt) |
| SG (1) | SG11201605121VA (pt) |
| WO (1) | WO2015123174A1 (pt) |
| ZA (1) | ZA201604613B (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103930407B (zh) * | 2011-09-12 | 2019-02-26 | 默克专利有限公司 | 用作激酶活性调节剂的氨基嘧啶衍生物 |
| SG10201900954SA (en) | 2013-03-11 | 2019-02-27 | Merck Patent Gmbh | Heterocycles as Modulators of Kinase Activity |
| US11866421B2 (en) | 2021-05-31 | 2024-01-09 | Epigen Biosciences, Inc. | Pyrimidine and pyridine amine compounds and usage thereof in disease treatment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20110843A1 (es) * | 2008-09-22 | 2011-12-08 | Cayman Chem Co | Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica |
| AR074072A1 (es) * | 2008-11-11 | 2010-12-22 | Lilly Co Eli | Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme |
| EP2627650A2 (en) * | 2010-05-26 | 2013-08-21 | Merck Sharp & Dohme Corp. | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 |
| CN103930407B (zh) * | 2011-09-12 | 2019-02-26 | 默克专利有限公司 | 用作激酶活性调节剂的氨基嘧啶衍生物 |
| JP5964974B2 (ja) * | 2011-09-12 | 2016-08-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | キナーゼ活性のモジュレーターとしての新規イミダゾールアミン |
| SG10201900954SA (en) * | 2013-03-11 | 2019-02-27 | Merck Patent Gmbh | Heterocycles as Modulators of Kinase Activity |
-
2015
- 2015-02-10 JP JP2016551740A patent/JP6560243B2/ja not_active Expired - Fee Related
- 2015-02-10 BR BR112016015285A patent/BR112016015285A8/pt not_active Application Discontinuation
- 2015-02-10 WO PCT/US2015/015136 patent/WO2015123174A1/en active Application Filing
- 2015-02-10 CA CA2935600A patent/CA2935600A1/en not_active Abandoned
- 2015-02-10 EP EP15706605.1A patent/EP3105224A1/en not_active Ceased
- 2015-02-10 US US14/618,122 patent/US9434714B2/en not_active Expired - Fee Related
- 2015-02-10 CN CN201580007838.6A patent/CN105980375A/zh active Pending
- 2015-02-10 KR KR1020167019279A patent/KR20160110953A/ko not_active Application Discontinuation
- 2015-02-10 AU AU2015217397A patent/AU2015217397B2/en not_active Ceased
- 2015-02-10 MX MX2016010268A patent/MX2016010268A/es unknown
- 2015-02-10 SG SG11201605121VA patent/SG11201605121VA/en unknown
- 2015-02-10 RU RU2016135420A patent/RU2690679C2/ru not_active IP Right Cessation
-
2016
- 2016-07-06 ZA ZA2016/04613A patent/ZA201604613B/en unknown
- 2016-07-27 IL IL246973A patent/IL246973A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2690679C2 (ru) | 2019-06-05 |
| CN105980375A (zh) | 2016-09-28 |
| AU2015217397B2 (en) | 2019-01-17 |
| AU2015217397A1 (en) | 2016-07-07 |
| US9434714B2 (en) | 2016-09-06 |
| RU2016135420A3 (pt) | 2018-09-27 |
| CA2935600A1 (en) | 2015-08-20 |
| RU2016135420A (ru) | 2018-03-15 |
| BR112016015285A8 (pt) | 2020-06-09 |
| KR20160110953A (ko) | 2016-09-23 |
| IL246973A0 (en) | 2016-09-29 |
| JP2017505799A (ja) | 2017-02-23 |
| MX2016010268A (es) | 2016-10-13 |
| WO2015123174A1 (en) | 2015-08-20 |
| SG11201605121VA (en) | 2016-07-28 |
| EP3105224A1 (en) | 2016-12-21 |
| ZA201604613B (en) | 2018-11-28 |
| JP6560243B2 (ja) | 2019-08-14 |
| US20150225371A1 (en) | 2015-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017001058A2 (pt) | inibidores derivados de 2-h-indazole como quinase ciclina dependente (cdk) e seus usos terapêuticos | |
| BR112016016158A2 (pt) | Derivados de heterociclila bicíclicos como inibidores de irak4, sua composição farmacêutica e seus usos | |
| BR112016021962A2 (pt) | Compostos, composição farmacêutica e seus usos como moduladores de ror gama | |
| PH12019500176A1 (en) | Heterocyclic compounds and ther uses | |
| BR112016023422A2 (pt) | Dispersão seca por spray, composição farmacêutica e seus usos, kit e comprimido | |
| CL2014003531A1 (es) | Suministro de farmaco diodegradable para las composiciones hidrofóbicas y su metodo de preparacion. | |
| CL2016001895A1 (es) | Compuestos | |
| BR112017001678A2 (pt) | Método para a preparação de (4s)-4-(4-ciano-2- metoxi-fenil)-5-etoxi-2,8-dimetil-1,4-di-hidro-1-6- naftiridina-3-carboxiamida e purificação do mesmo para uso como um ingrediente ativo farmaceutico | |
| BR112017025542A2 (pt) | compostos de naftiridina como inibidores de quinase jak | |
| BR112018000129A2 (pt) | oxiesteróis e seus métodos de utilização | |
| BR112013023816A2 (pt) | solução ou formulação estabilizada, seu método de preparação, métodos de aplicação e usos | |
| BR112016022814A2 (pt) | composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico | |
| CL2016002300A1 (es) | Combinaciones de principios activos insecticidas y nematocidas | |
| BR112016000779A2 (pt) | inibidores de autotaxina que compreendem núcleo do ciclo de benzilamida de anel heteroaromático, seus usos, composição e combinação farmacêuticas | |
| CL2014002358A1 (es) | Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolin-4(3h)-ona; metodos de preparacion; composiciones farmaceuticas que las comprenden y uso en el tratamiento del cancer. | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| BR112016018062A2 (pt) | compostos terapêuticos, composição farmacêutica e usos | |
| FR22C1058I2 (fr) | Formulation de comprimé de 2-fluoro-n-méthyl-4-[7-(quinoline -6-ylméthyl) imidazo[1,2-b][1,2,4]triazine -2-yl]benzamide | |
| DK3288940T5 (da) | Azabenzimidazoler og deres anvendelse som ampa-receptormodulatorer | |
| BR112016027379A2 (pt) | formulações tópicas e seus usos | |
| MX2015012416A (es) | Compuestos heterociclicos y sus usos. | |
| BR112016026552A2 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
| BR112016027383A2 (pt) | Derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação | |
| ZA201708773B (en) | Agent for promoting migration of pluripotent stem cells | |
| BR112015010271A2 (pt) | produto de comicronização, composição farmacêutica e seus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |